These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 1674549)

  • 21. Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.
    Hwang SS; Boyle TJ; Lyerly HK; Cullen BR
    Science; 1992 Jul; 257(5069):535-7. PubMed ID: 1636088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increase in sensitivity to soluble CD4 by primary HIV type 1 isolates after passage through C8166 cells: association with sequence differences in the first constant (C1) region of glycoprotein 120.
    Orloff SL; Bandea CI; Kennedy MS; Allaway GP; Maddon PJ; McDougal JS
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):335-42. PubMed ID: 7786580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between kinetics of soluble CD4 interactions with HIV-1-Env-expressing cells and inhibition of syncytia formation: implications for mechanisms of cell fusion and therapy for AIDS.
    Dimitrov DS; Hillman K; Manischewitz J; Blumenthal R; Golding H
    AIDS; 1992 Mar; 6(3):249-56. PubMed ID: 1348943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.
    Ho HT; Fan L; Nowicka-Sans B; McAuliffe B; Li CB; Yamanaka G; Zhou N; Fang H; Dicker I; Dalterio R; Gong YF; Wang T; Yin Z; Ueda Y; Matiskella J; Kadow J; Clapham P; Robinson J; Colonno R; Lin PF
    J Virol; 2006 Apr; 80(8):4017-25. PubMed ID: 16571818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.
    O'Brien WA; Mao SH; Cao Y; Moore JP
    J Virol; 1994 Aug; 68(8):5264-9. PubMed ID: 8035523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetics of HIV-1 interactions with sCD4 and CD4+ cells: implications for inhibition of virus infection and initial steps of virus entry into cells.
    Dimitrov DS; Willey RL; Martin MA; Blumenthal R
    Virology; 1992 Apr; 187(2):398-406. PubMed ID: 1347667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
    Daar ES; Li XL; Moudgil T; Ho DD
    Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6574-8. PubMed ID: 2395859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120.
    Maeda Y; Matsushita S; Hattori T; Murakami T; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2049-54. PubMed ID: 1493053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding.
    Sattentau QJ; Moore JP; Vignaux F; Traincard F; Poignard P
    J Virol; 1993 Dec; 67(12):7383-93. PubMed ID: 7693970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.
    Callahan LN; Phelan M; Mallinson M; Norcross MA
    J Virol; 1991 Mar; 65(3):1543-50. PubMed ID: 1995952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro.
    Cordell J; Moore JP; Dean CJ; Klasse PJ; Weiss RA; McKeating JA
    Virology; 1991 Nov; 185(1):72-9. PubMed ID: 1718090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity.
    Dirckx L; Lindemann D; Ette R; Manzoni C; Moritz D; Mous J
    Virus Res; 1990 Dec; 18(1):9-20. PubMed ID: 2082620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression.
    Cavacini LA; Emes CL; Power J; Underdahl J; Goldstein R; Mayer K; Posner MR
    J Acquir Immune Defic Syndr (1988); 1993 Oct; 6(10):1093-102. PubMed ID: 7692037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells.
    Schenten D; Marcon L; Karlsson GB; Parolin C; Kodama T; Gerard N; Sodroski J
    J Virol; 1999 Jul; 73(7):5373-80. PubMed ID: 10364284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    Moore JP; Ho DD
    J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles.
    Neurath AR; Strick N; Jiang S; Li YY; Debnath AK
    BMC Infect Dis; 2002 Apr; 2():6. PubMed ID: 11983022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG).
    Flasher D; Konopka K; Chamow SM; Dazin P; Ashkenazi A; Pretzer E; Düzgünes N
    Biochim Biophys Acta; 1994 Aug; 1194(1):185-96. PubMed ID: 8075135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
    Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV
    J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble CD4 enhances simian immunodeficiency virus SIVagm infection.
    Werner A; Winskowsky G; Kurth R
    J Virol; 1990 Dec; 64(12):6252-6. PubMed ID: 1700834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AFM force measurements of the gp120-sCD4 and gp120 or CD4 antigen-antibody interactions.
    Chen Y; Zeng G; Chen SS; Feng Q; Chen ZW
    Biochem Biophys Res Commun; 2011 Apr; 407(2):301-6. PubMed ID: 21382342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.